The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee.
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
Inflammatory myofibroblastic tumor of the prostate.
Fukiage K, Fujita K, Toyoda S, Nishimoto M, Kikuchi T, Chikugo T, Yoshimura K, Esa A, Ito A, Uemura H.
IJU Case Rep. 2024 Jan 18;7(2):141-143. doi: 10.1002/iju5.12687. eCollection 2024 Mar.
Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review.
de Pablos-Rodríguez P, Del Pino-Sedeño T, Infante-Ventura D, de Armas-Castellano A, Ramírez Backhaus M, Ferrer JFL, de Pablos-Velasco P, Rueda-Domínguez A, Trujillo-Martín MM.
J Clin Med. 2022 Dec 21;12(1):57. doi: 10.3390/jcm12010057.
Serous borderline tumor of the paratestis: a report of seven cases.
McClure RF, Keeney GL, Sebo TJ, Cheville JC.
Am J Surg Pathol. 2001 Mar;25(3):373-8. doi: 10.1097/00000478-200103000-00012.
Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists.
Varma M, Egevad L, Algaba F, Berney D, Bubendorf L, Camparo P, Comperat E, Erbersdobler A, Griffiths D, Grobholz R, Haitel A, Hulsbergen-van de Kaa C, Langner C, Loftus B, Lopez-Beltran A, Mayer N, Nesi G, Oliveira P, Oxley J, Rioux-Leclercq N, Seitz G, Shanks J, Kristiansen G.
J Clin Pathol. 2016 Oct;69(10):852-7. doi: 10.1136/jclinpath-2016-203658. Epub 2016 Feb 29.
Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
Masic S, Washington SL 3rd, Carroll PR.
Curr Opin Urol. 2017 May;27(3):231-237. doi: 10.1097/MOU.0000000000000387.
Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.
BJU Int. 2012 Aug;110(3):353-62. doi: 10.1111/j.1464-410X.2011.10751.x. Epub 2011 Nov 11.
Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.
Szulkin R, Clements MS, Magnusson PKE, Wiklund FE, Kuja-Halkola R.
Prostate. 2017 Jun;77(8):900-907. doi: 10.1002/pros.23344. Epub 2017 Mar 1.
The use of immunohistochemistry for diagnosis of prostate cancer.
Leite KR, Srougi M, Sanudo A, Dall'oglio MF, Nesrallah A, Antunes AA, Cury J, Camara-Lopes LH.
Int Braz J Urol. 2010 Sep-Oct;36(5):583-90. doi: 10.1590/s1677-55382010000500008.
Clarifying the PSA grey zone: The management of patients with a borderline PSA.
Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P.
Int J Clin Pract. 2016 Nov;70(11):950-959. doi: 10.1111/ijcp.12883. Epub 2016 Sep 27.
